ASH 2021 Conference Coverage on VuMedi

 

ASH 2021 Conference Coverage on VuMedi
Avatar

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib Therapy Following Prior Ruxolitinib Failure: Real-World Assessment of Spleen, Symptoms, and Hematologic Response

By ASH 2021 Conference Coverage on VuMedi FEATURING John Mascarenhas
By ASH 2021 Conference Coverage on VuMedi FEATURING John Mascarenhas
608 views
December 15, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
MDS and MPN
06:20
ASH 2021 Conference Coverage on VuMedi

Retrospective Head-to-Head Comparison Between Pacritinib and Ruxolit…

Feat. J. Mascarenhas
07:13
ASH 2021 Conference Coverage on VuMedi

FDA Approval and Safety Analysis of Pacritinib in Patients With Myel…

Feat. J. Mascarenhas
10:26
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on a Pooled Analysis of the COMFORT-I & II Stud…

Feat. S. Verstovsek
06:04
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Pathological Characteristics of Hypocellular M…

Feat. K. Kim
05:14
ASH 2021 Conference Coverage on VuMedi

ASH 2021 NGS Evaluation of the EQoL-MDS Trial: Preliminary Analysis …

Feat. E. Oliva
11:04
ASH 2021 Conference Coverage on VuMedi

ASH 2021: Evaluation of IWG 2006 Response Criteria in Patients with …

Feat. J. Bewersdorf
06:52
ASH 2021 Conference Coverage on VuMedi

ASH 2021: A Phase 3 Study of Hepcidin Mimetic Rusfertide in Patients…

Feat. S. Verstovsek
11:17
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Management of Polycythemia Vera

Feat. A. Kuykendall
04:45
ASH 2021 Conference Coverage on VuMedi

ASH 2021 on LR-MDS: Factors Predicting Progression to HR-MDS and AML…

Feat. A. Jain
08:59
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the Outcomes of Therapy-Related Myeloid Neoplasms…

Feat. M. Shah
08:12
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Efficacy and Safety of Parsaclisib+Ruxolitinib Combination …

Feat. A. Yacoub
08:30
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Presentation on Tagraxofusp, a First-in-Class CD123-Targete…

Feat. A. Yacoub
05:32
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Ruxolitinib + Parsaclisib for JAK-/PI3K-Inhib…

Feat. A. Yacoub
08:15
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights in MPN

Feat. P. Bose
15:25
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Clinical and Translational Data From the Ongoing MANIFEST T…

Feat. M. Kremyanskaya
10:43
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Final Results of a Phase 2 Study of Sotatercept for Anemia …

Feat. P. Bose
05:06
ASH 2021 Conference Coverage on VuMedi

Positioning Fedratinib in the Treatment Strategy of Myelofibrosis

Feat. F. Passamonti
13:17
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Molecular Responses in Treatment-Naïve HR-MDS Patients Trea…

Feat. J. Garcia
12:03
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Highlights on Efficacy and Safety of Sabatolimab for Patien…

Feat. A. Brunner
06:27
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Updates on the Phase 2 Study of Bomedemstat (IMG-7289) In P…

Feat. H. Gill
07:56
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1…

Feat. J. Mascarenhas
10:27
Richard T. Silver

Splenomegaly in Polycythemia Vera: Clinical Significance and Relatio…

10:44
Aaron Gerds

A Real-World Evaluation of the Association Between Elevated Blood Co…

15:40
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on the “AAA” Risk Model for Essential Thrombocythemi…

Feat. A. Tefferi
05:15
ASH 2021 Conference Coverage on VuMedi

ASH 2021 Update on Clinical Outcomes at 3 and 6 Months of Fedratinib…

Feat. J. Mascarenhas